Google
SNTI — SENTI BIOSCIENCES INC (Healthcare >> Biotechnology)
SNTI FAQ
What is SNTI's ROE?
SENTI BIOSCIENCES INC reports a Return on Equity (ROE) of -2,009.63%.
What is SNTI's dividend yield?
SENTI BIOSCIENCES INC offers a dividend yield of 0.00%.
What is SNTI's Deepscope Quality Score?
Deepscope rates SNTI's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy SNTI?
Deepscope's AI Timing Score for SNTI is 63 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does SNTI belong to?
SENTI BIOSCIENCES INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 1.00
Price
0.02
(2.53%)
Day Change
|
|
|---|
SNTI, the overall quality is not good ( Quality = 23) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 93 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.00 |
| PBV / Sector |
11.84 / 4.58
|
| Earning Per Share | -1.70 |
| PE / Sector |
N/A / 17.10
|
| PEG or PE/Growth / Sector |
N/A / 0.52
|
| Average 1M Daily Value |
0.20 M
GREAT
|
| Average 1W Daily Value |
0.19 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
43% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-05 09:11:52 |
| Symbol | SNTI |
| Name | SENTI BIOSCIENCES INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 31.14 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 30.38 / 8,655.90 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 2 Corporate Drive, South San Francisco, CA, United States, 94080
Phone: 650 239 2030
Website: https://www.sentibio.com
Sector: Healthcare >> Biotechnology
Description: Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. It offers SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia. In addition, the company develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to cell therapies for regenerative medicines. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd. The company was formerly known as Senti Biosciences, Inc. and changed its name to Senti Biosciences Holdings, Inc. in April 2026. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
